Document is current
Any future updates will be listed below
-
Authors
Mokgokong, Ruth https://orcid.org/0000-0002-6278-4969
Cislo, Paul https://orcid.org/0009-0004-3130-2818
Tudone, Elena https://orcid.org/0009-0005-0406-7565
Weinstein, Edward
Cappelleri, Joseph C. https://orcid.org/0000-0001-9586-0748
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 12 March 2026
First Online: 19 March 2026
Declarations
:
: Participants provided written informed consent before enrolling in the EPIC-IC trial [ ]. Ethics approval for the protocol, amendments, and other relevant documents was granted by each institution’s review boards and ethics committees. Investigator names and approving ethics committees are listed in Weinstein, et al., 2025 [ ]. The study was conducted in accordance with consensus ethical principles, including those in the Declaration of Helsinki and the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines; with applicable International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guidelines for Good Clinical Practice; and with applicable laws and regulations, including applicable privacy laws.
: Not applicable.
: RM, PC, ET, EW, and JCC are employees and minority shareholders of Pfizer, which funded this study.
